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Abstract: Patients with rheumatoid arthritis (RA), especially those who are treated with methotrexate (MTX), might have 
an increased risk of Hodgkin lymphoma (HL), a malignancy that is associated with Epstein-Barr virus (EBV). Here we 
describe a monoclonal EBV-infected B-lymphoblastoid cell line (LCL) called TKS-1 that was established from cells that 
spontaneously converted from an MTX-treated RA patient. TKS-1 has properties similar to HL cells and it is distinctly 
different from control LCLs established from normal individuals. TKS-1 cells express the HL -associated surface markers 
CD15 and CD30 (Takei et al. 1989). Like Hodgkin Reed-Sternberg (H-RS) cells of EBV-positive HL, TKS-1 cells 
express EBNA1 mRNA transcribed from the Qp promoter of the virus, whereas control LCLs use the Cp or Wp promoter 
to transcribe mRNA. TKS-1 cells can proliferate in an anchorage-independent manner and possess a cloning efficiency 
comparable to that of the Burkitt lymphoma (BL) line Raji. In addition, two EBV-positive LCLs established by 
cocultivated CD34+ cells isolated from the bone marrow of patients with RA and peripheral blood B lymphocytes from a 
healthy EBV-seronegative individual also expressed CD15. These results indicate that EBV-infected B-lymphoblastoid 
cells from patients with RA tend to acquire properties similar to HL cells. 
INTRODUCTION 
  The relationship between rheumatoid arthritis (RA) and 
Epstein-Barr virus (EBV)-associated lymphoproliferative 
disorders including Hodgkin lymphoma (HL) is inconclusive 
and controversial. We previously established a monoclonal 
EBV-infected B-lymphoblastoid cell line (LCL) called TKS-
1 [1]. The disease-modifying anti-rheumatic drug (DMARD) 
methotrexate (MTX) sometimes causes malignancies of this 
type [2] and in some patients these EBV-associated 
lymphomas completely regress when MTX therapy is 
reduced or discontinued [3]. Mariette et al. have performed a 
nationwide prospective study that suggests an increased risk 
for HL [4], but not for non-Hodgkin lymphoma (NHL) in 
patients with RA who are treated with MTX. However, 
Baecklund et al.
 demonstrated on 378 consecutive Swedish 
patients with RA that the most common DMARDs including 
MTX are not in themselves a risk factor for RA-associated 
lymphomas, nor does treatment further increase the risk 
associated with high inflammatory activity [5]. Although 
most “excess” lymphomas in RA are of the aggressive 
diffuse large B cell lymphoma type, the presence of EBV in 
RA-associated lymphomas is low. 
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  The CD15 antigen is a marker of granulocytes, 
macrophages and activated T cells and 37-100% of Hodgkin-
Reed Sternberg (H-RS) cells and the malignant cells of HL 
are positive for this antigen [6]. The CD15 antigen binds to 
the adhesion molecule, P-selectin [7] and the anti-CD15 
antibody recognizes the sugar moiety lacto-N-fucopentaose-
III (LNF-III) [8, 9] or Lewis X antigen. P-selectin is an 
external membrane protein on activated platelets that has 
also been referred to as platelet activation-dependent 
granule-external membrane protein (PADGEM), granule 
membrane protein 140 (GMP-140) or CD62 [10, 11]. 
  An association between RA and EBV is also recognized 
[12-14]. Direct evidence includes a demonstration of EBV-
encoded small nuclear RNA (EBER-1) and latent membrane 
protein (LMP)-1 in the synovial cells of RA [15]. Other 
studies subsequently confirmed this finding [16-20] except 
for one that did not find evidence of EBV infection in a 
synovial lesion of RA [14]. Another notable finding 
associating EBV with RA is that the expression of signalling 
lymphocytic-activation molecule associated protein (SAP) 
transcripts is decreased in T cells from RA patients [21]. 
This protein plays an essential role in cytotoxic T and NK 
cells that are involved in the immune response to EBV. 
  To gain insight into the relationships between each of 
EBV and RA with HL, we characterized the surface 
phenotypes, EBV gene expression, and malignant potential 
of EBV-infected lymphoblastoid cell line (LCL) (TKS-1) 
established from a patient with RA and found that these cells 
tended to acquire properties similar to those of HL cells. 42   The Open Rheumatology Journal, 2009, Volume 3  Inomata et al. 
MATERIALS AND METHODS 
Cells  
  Peripheral blood mononuclear cells from a patient with 
RA were stimulated with phorbol myristate acetate (PMA) to 
establish the EBV
+ B lymphoblastoid cell line TKS [1]. Two 
subclones (type 1 & 2) of TKS were isolated by repeated 
limiting dilution in 96-well micro-culture plates. The 
phenotypes of these clones were CD15
+ CD30
+ CD19
+ 
CD20
+ (type 1) and CD15
+ CD30
+ CD19
– CD20
+ (type 2) 
(Fig. 1). The type 1 subclone of TKS cells (TKS-1) reacted 
with the following antibodies against surface antigens: Ig 
light chain kappa, HLA-DR, Leu 10, Leu 12 (CD19), Leu 16 
(CD20), Leu M1 (CD15), and Ki-1 (CD30). These cells did 
not react against the antibodies OKM1 (CD11b), Leu M2, 
Leu M3 (CD14), Leu M4, or to T cell surface or natural 
killer cell antigens. TKS-1 cells were peroxidase-negative, 
slightly positive for non-specific esterase that was not 
inhibited by NaF, had monoclonal immunoglobulin light 
chain gene rearrangement and expressed EBNA-1 mRNA 
[1]. The RABM/EBV
+ 1-3 cell lines are EBV
+ LCLs that 
were established by co-cultivating bone marrow CD34
+ cells 
obtained from RA patients with peripheral B cells isolated 
from an EBV-seronegative healthy individual [22]. Akata 
and Raji are EBV
+ Burkitt lymphoma (BL) cell lines, BJAB 
is an EBV-negative B lymphoma line [23]. GL-1 and CBL2 
are EBV
+ LCL established by infecting peripheral B cells 
from a healthy donor with EBV, and DI-1 and DI-5 are 
LCLs that were spontaneously established from an EBV 
seropositive donor. Table 1 summarizes the cell lines used in 
this study. All cell lines were cultured in RPMI 1640 
supplemented with 10% heat-inactivated fetal calf serum 
(FCS) and antibiotics. 
Table 1.  Cell Lines Used in this Study and Positive Ratio of 
CD15/CD19 
 
Cell Line  Origin of Cell Lines   CD15/CD19 
TKS 
Mononuclear cells from peripheral blood of 
RA patient were cultured with PMA for4 
weeks and then clusters formed 
+ 
TKS-1  TKS as described above, subclone. Two 
limiting dilutions performed 
+++ (98%) 
RABM/EBV+1 
2 
3 
EBV positive B cell lines obtained by co- 
cultured RA bone marrow CD34
+ cells and 
normal EBV negative peripheral B cells 
- 
+++ (83) 
+++ (86) 
B95-8 LCL 
Normal B cell line transformed with B95-8 
supernatant. Normal donor is same as 
RABM/EBV1-3 described above. 
± 
Akata, BJAB, 
Raji   
Burkitt lymphoma cell lines GL-1 and CBL2 
are EBV
+ LCL 
- 
GL-1 and 
CBL2, DI-1, 
DI-5 
Established by infecting peripheral B cells 
from healthy donor with EBV. DI-1 and DI-
5 are LCLs spontaneously established from 
EBV-seropositive donor 
- 
 
Monoclonal Antibodies (mAbs) and Flow Cytometry 
  The mAbs Leu M1, Leu 12 and Leu 16 were purchased 
from Becton Dickinson (Sunnyvale, CA, USA), and the mAb 
Ki-1 was obtained from Dakopatts (Glostrup, Denmark). 
Fluorescein isothiocyanate (FITC)- or phycoerythrin (PE)-
conjugated mouse IgG used as a control and PE-conjugated 
anti-mouse IgG as the second antibody were purchased from 
Dakopatts. The reactivity of cell lines with these antibodies 
was analyzed using flow cytometers (Cyto ACE-150, Nippon 
Bunko, Tokyo and FACSCalibur, Becton Dickinson). 
Stimulation with PMA  
  TKS-1 and Raji cells (both 5 x 10
5/ml) were resuspended 
in fresh culture medium containing 10 ng/ml of PMA. Two-
thirds of the medium was replaced every 2 days with fresh 
medium containing PMA for 7 days. Control cells were 
cultured in solvent medium. The expression of CD15, CD30, 
CD19, and CD20 was examined by staining the cells at 0, 3, 
5 and 7 days after starting the experiment. TKS-1 and Raji 
cell viability exceeded 80% throughout the experiments, 
which were performed in three flow cytometry studies. 
Western Blotting  
  Cells were lysed in SDS sample buffer, fractionated by 
SDS-PAGE and then transferred to nitrocellulose 
membranes. Non-specific binding was blocked with 5% non-
fat milk and the membranes were incubated with 
appropriately diluted antibodies. The EBNA-1 and EBNA-2 
proteins and LMP-1 were
  detected using serum from an 
individual who was EBV-seropositive, and the PE2 (DAKO, 
Denmark) and S12 mAbs, respectively. The membranes 
were then incubated with horseradish peroxidase-conjugated 
anti-mouse
 antibody and proteins were visualized using an 
enhanced chemiluminescence assay (GE Healthcare). 
Analysis of Promoter Usage for EBNA-1 in CD15
+ B 
Cells  
  First-strand cDNA was synthesized from total RNA (5 
g) extracted from each cell line using TRIzol (Invitrogen), 
oligo (dT) primers and the SuperScript III first strand synthesis 
system (Invitrogen) according to the manufacturer’s instructions. 
We performed RT-PCR using the Cp-mRNA-specific primers, 
5’-CATCTAAACCGACTGAAGAA-3’ (sense) and 5’-CCC 
TGAAGGTGAACCGCTTA-3’ (antisense); Wp-mRNA-
specific primers, 5'-GTCCACACAAATCCTAG-3' (sense) 
and 5'-CCCTGAAGGTGAACCGCTTA-3' (antisense); 
Cp/Wp-EBNA1-specific primers, 5'-TGGCGTGTGACGTG 
GTGTAA-3' (sense) and 5'-CATTTCCAGGTCCTGTACC 
T-3' (antisense); Qp-EBNA1-specific primers, 5'-GTGCGC 
TACCGGATGGCG-3' (sense) and 5'-CATTTCCAGGTC 
CTGTACCT-3' (antisense); or the 18S ribosomal RNA-
specific primers 5’-TACATGCCGACGGGCGCTGACC-3’ 
(sense) and 5’-CCTGCTGCCTTCCTTGGATG-3’ (antisense). 
Transcripts were amplified using a GeneAmp PCR System 
9700 thermocycler (Applied Biosystems, Foster City, CA) 
and Paq5000 DNA polymerase (Stratagene, La Jolla, CA, 
USA) in a total volume of 50l for 30-35 cycles, and the 
PCR products were analyzed by 2% agarose gel 
electrophoresis. 
Agarose Clonability Assays  
  Cells (100 or 500) suspended in the top layer of 0.33% 
agar in RPMI 1640 containing 10%
 FBS were poured onto a 
basal layer of 0.5% agar in RPMI 1640 containing 10% FBS 
in
  35-mm plates, and incubated at 37°C for 26 days. 
Colonies were counted under a microscope. EBV+CD15+ B Cells from Patients with Rheumatoid Arthritis  The Open Rheumatology Journal, 2009, Volume 3   43 
RESULTS 
Effects of PMA Stimulation on CD15
+ B Cells 
  We previously showed that TKS-1 cells express the two 
HL markers CD15 and CD30 [1]. Since a study has 
described a change in the expression of these HL markers in 
H-RS cells after stimulation with the tumour promoter 
phorbol-12- myristate-13-acetate (PMA) [24], we examined 
their expression in PMA-stimulated TKS-1 cells. Fig. (2) 
shows the changes in the ratios (%) of TKS-1 or Raji cells 
that expressed CD15, CD30, CD19 or CD20 during PMA 
stimulation. Most TKS-1 cells remained CD15
+ for 7 days 
after PMA stimulation. CD30 expression gradually declined, 
and less than 50% of the cells were positive by day 7. CD19-
positive cells decreased rather quickly and only a few cells 
were positive by day 5. In contrast, the expression of CD19, 
CD20, CD15, and CD30 in Raji cells did not significantly 
change, and most cells remained for CD19 and CD20 
positive, and CD15 and CD30 negative. After more 
prolonged exposure to PMA, TKS-1 cells lost CD19 and 
CD20 expression, but continued to express both CD15 and 
CD30 (data not shown). Figs. (1, 2) shows representative dot 
plots of the flow cytometry data and mean fluorescence 
intensity (MFI) values. 
Analysis of EBV Gene Expression in TKS-1 Cells 
  Three types of latent EBV infection with distinct profiles 
of viral gene expression are recognized in various EBV-
related tumours and cell lines. The type I latency found in 
BL and gastric carcinoma cells is characterized by the 
expression of EBV nuclear antigen 1 (EBNA1) as the sole 
EBV protein. Type II latency represented by HLs, T-cell 
lymphomas and nasopharyngeal carcinomas is characterized 
by the expression of EBNA1, latent membrane protein 1 
(LMP1) and LMP2. The type III latency that occurs in LCLs 
established in vitro by EBV infection and lymphoproliferative 
disorder in immunocompromised hosts, is characterized by 
the expression of EBNA 1, 2, 3A, 3B and 3C, as well as 
LMPs 1, 2A and 2B, all of which are growth transformation-
associated viral proteins. Messenger RNAs coding for 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Cluster of differentiation positivity of subclones from TKS cells. Two TKS subclones (type 1&2) were isolated by repeated 
limiting dilution in 96-well micro-culture plates. The phenotypes of these clones were CD15
+ CD30
+ CD19
+ CD20
+ (type 1) and CD15
+ 
CD30
+ CD19
– CD20
+ (type 2). Type 1 TKS subclone (TKS-1) reacted with following antibodies against surface antigens: Ig light chain 
kappa, HLA-DR, Leu 10, Leu 12 (CD19), Leu 16 (CD20), Leu M1 (CD15), and Ki-1 (CD30). These cells were unreactive to antibodies 
OKM1 (CD11b), Leu M2, Leu M3 (CD14), Leu M4, or to T cell surface or natural killer cell antigens. Numbers in parentheses are MFI 
values. Dot plots show representative flow cytometry data. 44   The Open Rheumatology Journal, 2009, Volume 3  Inomata et al. 
EBNA1 as well as other EBNAs are transcribed from either 
of the Cp or Wp promoters of the virus in type III latency, 
whereas EBNA1 mRNA is transcribed from the Qp promoter 
in types I and II latency [25]. 
  We examined EBV gene expression to determine the 
type of EBV latency in TKS-1 cells. Fig. (3) shows that 
TKS-1 and its subclones expressed EBNA1 and LMP1 at 
similar levels to those in EBV-positive LCLs established 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Effects of PMA on surface makers of TKS-1 and Raji cells. TKS-1 and Raji cells (5 x 10
5 cells/ml each) were resuspended in 
fresh medium containing either 10 ng/ml PMA or solvent. Two-thirds of the medium was replaced with fresh medium every 2 days. 
Expression of CD15, CD30, CD19, and CD20 was examined by flow cytometry at 0, 1, 3, 5, 7 days after starting the experiment. Data are 
representative of three repeated experiments. Dot plots show representative flow cytometry data. EBV+CD15+ B Cells from Patients with Rheumatoid Arthritis  The Open Rheumatology Journal, 2009, Volume 3   45 
from normal individuals. In contrast, less EBNA2 was 
expressed in TKS-1 and its subclones than in other LCLs. 
Only EBNA1 was expressed in Akata cells that were 
examined as a reference for type I latency. 
RT-PCR Detection of Cp-mRNA, Wp-mRNA, Cp/Wp- 
Derived EBNA1, and Qp-Derived EBNA1 Transcripts 
  To determine which of the three possible EBNA 
promoters was used in TKS-1 cells and RABM/EBV
+1-3 
cell lines, we performed RT-PCR using the primer sets 
described in Materials and methods that distinguish mRNAs 
transcribed from Cp, Wp, and Qp, as well as total RNA 
isolated from BJAB, Akata, LCL/B95-8 and TKS-1. 
Ribosomal RNA (18S) served as the internal control. The 
results shown in Fig. (4) indicate that Qp is used in TKS-1 
cells similar to the Akata cell line with typical type I latency, 
but not in the EBV-transformed LCLs. Cp and Wp were 
used in the RABM/EBV
+ 1-3 cell lines and in regular LCLs, 
whereas Qp was not. 
Colony Formation by TKS-1 Cells in Soft Agar 
  We performed agarose clonability assays to measure the 
anchorage-independent growth of TKS-1 cells, thus 
indicating their malignant potential. Either 100 or 500 cells 
from the TKS-1, typical LCLs, or Raji lines were seeded in 
soft agar and then colonies were counted. While none of the 
three typical LCLs established from normal individuals 
formed colonies, TKS-1 and Raji cells generated the same 
number of colonies (Fig. 5). These results indicate that TKS-
1 cells have higher malignant potential than typical LCLs. 
Ratio of CD15 Cells in EBV
+ B Cell Lines 
 RABM/EBV
+1-3 cell lines are EBV-infected LCLs 
established by co-cultivating CD34
+ cells isolated from the 
bone marrow of a patient with RA and peripheral blood B 
lymphocytes obtained from an EBV-seronegative individual. 
HLA typing confirmed that these spontaneously established B 
cells were derived from a peripheral blood donor, and not 
from an RA patient.  The reactivity of these cell lines with 
monoclonal antibodies was analyzed by flow cytometry and 
the calculated double positive ratio of CD15
+/CD19
+ cells was 
3.7, 27.3, 83.4 and 85.8% in RABM/EBV
+1, B95-8 LCL, 
RABM/EBV
+2 and RABM/EBV
+3 cell lines, respectively 
(Table 1). In contrast, none of the regular LCLs established 
either spontaneously or by EBV infection in vitro expresses 
CD15. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). RT-PCR analysis to detect Cp-mRNA, Wp-mRNA, 
Cp/Wp-derived EBNA1, and Qp-derived EBNA1 transcripts. 
RT-PCR proceeded using primer sets described in Materials and 
Methods. Total RNA was isolated from BJAB, Akata, LCL/B95-8, 
RABM/EBV +1-3 and TKS-1. Ribosomal RNA (18S) served as 
internal control. 
DISCUSSION 
  This study demonstrated that TKS-1, an EBV-positive 
LCL cell line that was spontaneously established from a 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Western blot analysis of EBV gene expression in the TKS-1 cells. Expression of EBNA1 (top panel), EBNA2 (middle panel), 
and LMP1 (bottom panel) was examined in cell lysates of TKS-1, three subclones (1-3) of TKS-1, three (1-3) subclones of Akata, GL-1, 
CBL2, DI-1, and DI-5 by Western blotting as described in Materials and methods. Akata sublone 2 is an EBV
- clone that has lost EBV DNA 
and therefore does not express EBNA1. 46   The Open Rheumatology Journal, 2009, Volume 3  Inomata et al. 
patient with RA, expresses the HL markers CD15 and CD30 
[26], and that PMA altered their expression to levels similar to 
those of H-RS cells. Hsu and Hsu examined the effect of PMA 
on the surface phenotype of H-RS cells obtained from the 
spleens of patients with HL and showed that CD15 expression 
persisted for at least three days, whereas that of CD30 
gradually declined [24]. TKS-1 cells remained CD15 positive 
for 5 days, and then this condition persisted after PMA 
stimulation. In contrast, the expression of CD30 gradually 
decreased after adding TPA. CD19 expression was rapidly lost 
and remained almost undetectable after 3 days of PMA 
stimulation. Hsu and Hsu studied H-RS cells only at 3 days 
after starting PMA stimulation [24]. Therefore, the present 
data from TKS-1 cells cannot be precisely compared with 
those from H-RS cells. TKS-1 and H-RS cells both retain 
CD15 expression while gradually losing CD30 after PMA 
stimulation. In addition to TKS-1, RABM/EBV
+1-3 cells 
obtained by co-cultivating CD34
+ cells isolated from the bone 
marrow of a patient with RA and B lymphocytes obtained 
from healthy individuals also expressed CD15. Since the 
origin of RABM/EBV
+ cells are B lymphocytes obtained from 
EBV-seronegative individuals, the bone marrow CD34
+ cell 
preparation probably contained EBV, which transformed co-
cultivated B cells from a seronegative individual. Together 
with the results of the TKS-1 cells, this finding suggests that 
EBV strains harbored by patients with RA tend to induce 
CD15 expression. We determined that RABM/EBV
+ 1-3 cell 
lines used Cp and Wp, but not Qp. 
  TKS-1 cells express EBNA1, EBNA2, and LMP1 and in 
this sense can be categorized as latency III. However, low 
EBNA2 expression and usage of the Op promoter for EBNA1 
mRNA differ from those in regular LCLs and resemble the 
latency II type of H-RS cells in HL [27]. Thus we speculate 
that TKS-1 cells are intermediate between latency II and 
latency III with respect to EBV gene expression. In terms of 
malignant potential assessed by anchorage independent 
growth, TKS-1 cells clearly differed from regular LCLs 
established from normal individuals. While typical LCLs 
generated hardly any colonies in soft agar medium, TKS-1 
cells produced as many colonies as the BL Raji cells. Thus the 
malignant potential of TKS is much greater than that of 
regular LCLs and as high as that of Raji cells. To determine 
whether MTX affects EBV latency expression and 
malignancy, and whether CD15 plays any role in the growth 
of TKS-1 cells in soft agar would be of interest. These issues 
are under investigation. 
 Svensson  et al. have identified reversible EBV
– 
lymphadenopathy and bone marrow involved with HL in a 
single patient RA treated with MTX [28]. They suggest that 
most reported MTX-induced lymphomas have a background 
of RA, which itself confers an increased risk for the 
development of lymphoproliferative disorders. MTX-induced 
lymphoma in RA patients might not represent a distinct 
clinical entity, but rather reflect an increased risk of 
developing lymphoma that is inherent in this patient group 
[28]. Mariette et al. have performed a nationwide prospective 
study that suggests an increased risk for HL [4], but not for 
NHL, in RA patients treated with MTX. Furthermore, they 
concluded that the overall risk of NHL is not increased in RA 
treated with MTX. These MTX-related NHLs are resolved 
simply by drug withdrawal, whereas HL is often associated 
with EBV, refractory to MTX withdrawal, and requires 
chemoradiotherapy. This indicates that HL associated with RA 
has higher malignant potential [4, 29]. In fact, a large 
population-based case-control study has shown that a 
statistically significant increased risk of HL is associated with 
a history of several autoimmune conditions, including RA. 
Miyazaki  et al. examined the latency pattern of EBV and 
found that 2 of 9 patients who achieved a complete response 
had latency type III. Another whose disease stabilized had 
latency type II. The former two went into remission after 
MTX withdrawal especially in NHL with latency type III 
infection. Miyazaki et al. thus suggested that analysis of EBV 
infection, including latency types, is useful to decide optimal 
therapeutic strategies [30]. 
  In conclusion, the results presented herein suggest that 
CD15+ EBV-infected LCLs from patients with RA tend to 
acquire properties that differ from those of regular LCLs and 
are similar to those of H-RS cells of HL. These findings may 
provide an insight into the mechanism of development of HL 
in patients with RA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Anchorage-independent growth of TKS-1 cells in soft agar. Either 100 (left panel) or 500 (right panel) TKS, GL-1, CBL2, DI-5 and 
Raji lines were seeded in soft agar and then colonies were counted 26 days later. Data represent means ± SEM. EBV+CD15+ B Cells from Patients with Rheumatoid Arthritis  The Open Rheumatology Journal, 2009, Volume 3   47 
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